Case Studies
Case Studies
Track Record
Industry-Leading Track Record Extensive experience across life science fields
- 19 cases
- Productivity Improvement
- 12 cases
- Quality Improvement
- 15 cases
- Material Cost Reduction
- 16 cases
- R&D Period Reduction
Interviews
Client Interviews
Astellas Pharma
Building the Future of Cell Therapy: How AI and Robotics Are Revolutionizing Manufacturing
Astellas Pharma partnered with Robotic Biology Institute and Epistra to implement AI and robotics in cell therapy manufacturing, achieving a CV of 5.9% and discovering conditions yielding 50-100x greater yields within three months.
Shimadzu Corporation
Pioneering the Future of Cell Culture with "CellTune"
Shimadzu Corporation and Epistra jointly developed "CellTune," a culture optimization software that leverages AI to determine optimal cell culture conditions from LC/MS analysis data. The project progressed from inception to product release in just two years.
Vision Care
Searching for Cell Recipes for Regenerative Medicine Using AI
Vision Care and Epistra combined AI and robotics to optimize iPS cell differentiation induction conditions, achieving efficiency equal to or greater than that of experienced technicians and enabling application to cell manufacturing processes for regenerative medicine.
Spiber
Reducing R&D from Two Years to a Few Weeks: Discovering Conditions for High-Yield Structural Protein Production with AI
Spiber and Epistra collaborated to dramatically accelerate bioprocess optimization using AI, compressing what typically required two years of R&D into just a few weeks and discovering condition combinations humans would never consider.
More Cases
Additional Case Studies
-
Biopharmaceuticals
Cell Culture Media Development for Antibody Drug Manufacturing
- 40% Improvement in Antibody Production
Using CellTune, our culture optimization software powered by Epistra Accelerate, we improved the feed media composition for antibody production. As a result of the optimization, we discovered a media composition that increased antibody production by approximately 40% compared to the pre-optimization composition.
-
Assay Development
Novel Assay System Construction
- 46% Improvement in Detection Sensitivity
- 44% Reduction in R&D Period
We optimized conditions for a novel assay for drug screening. Human researchers and Epistra Accelerate independently conducted the optimization and compared results. The conditions discovered by Epistra Accelerate improved pre-optimization sensitivity by 46% and exceeded human-discovered conditions by 12%. While human researchers took 4.5 months, Epistra Accelerate completed the exploration in 2.5 months, achieving a 44% reduction in R&D time.
-
Cryopreservation
Improving Cell Preservation Reagent Performance
- 133% Improvement in Yield
- 40% Improvement in Functionality
- Robust Against Temperature/Concentration Changes
We developed a higher-performance cell preservation reagent for the commercialization of cell-based therapeutics. Through optimization, we identified a reagent composition that improved yield by 133% and cell functionality by 40% compared to commercially available products. The identified composition is also robust against temperature and concentration variations, while avoiding third-party intellectual property.
-
Cell Therapy
Culture Media Cost Reduction
- 70% Cost Reduction
Culture media costs for pharmaceutical manufacturing are high. We undertook an initiative to minimize media costs while maintaining comparable performance to improve profitability. Through optimization, we achieved a 70% reduction in total media costs, with projected ongoing savings of over 400 million yen per year.
-
Cell Therapy
Animal Origin-Free (AOF) Medium Development
- Significant Yield Improvement
- Achieved AOF
We optimized the media composition for the client's mesenchymal stem cells (MSC) using Epistra Accelerate. After 4 months of condition screening, we discovered a media composition with superior proliferative capacity and significantly reduced raw material costs. All media developed in this project are animal origin-free (AOF), containing no animal or human-derived factors.
Applications
Applicable to a Wide Range of Use Cases
- Antibody Drugs
- Cryopreservation Solutions
- Chemically Defined Media
- Regenerative Medicine
- Bio-manufacturing
- Vaccine Manufacturing
- Breeding
- Assay Development
Contact
Get in Touch
We work closely with our clients, providing optimal solutions tailored to their needs. Feel free to reach out.